NCHR Testimony at FDA on Sugammadex

November 6, 2016. Since sugammadex has the ability to quickly reverse the paralysis induced by neuromuscular blockers like rocuronium, it represents an innovative new option to improve surgical recovery. However, as with every new drug, we need to be certain the benefits outweigh the harms.

Read More »

NCHR Testimony Before FDA Advisory Panel on Flibanserin

June 4, 2015. The Center strongly supports research to advance understanding of, and solutions to, women’s lack of sexual desire. We understand that it is a real and distressing problem for many women. We have followed the regulatory history of flibanserin. Based on our analysis of the study results available today, we conclude that the benefits of this drug do not outweigh the risks. We ask the Advisory Committee to vote against approval of this drug.

Read More »
Page 20 of 42« First...10...1819202122...3040...Last »